BG103722A - Penylxanthine esters and amides - Google Patents

Penylxanthine esters and amides

Info

Publication number
BG103722A
BG103722A BG103722A BG10372299A BG103722A BG 103722 A BG103722 A BG 103722A BG 103722 A BG103722 A BG 103722A BG 10372299 A BG10372299 A BG 10372299A BG 103722 A BG103722 A BG 103722A
Authority
BG
Bulgaria
Prior art keywords
amides
esters
integer
methyl
value
Prior art date
Application number
BG103722A
Other languages
Bulgarian (bg)
English (en)
Inventor
Susan DALUGE
Douglas LIVINGSTONE
Gerald Wolberg
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of BG103722A publication Critical patent/BG103722A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG103722A 1997-02-14 1999-09-09 Penylxanthine esters and amides BG103722A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9703044.9A GB9703044D0 (en) 1997-02-14 1997-02-14 Phenyl xanthine esters and amides
PCT/EP1998/000784 WO1998035966A1 (en) 1997-02-14 1998-02-12 Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-yl)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders

Publications (1)

Publication Number Publication Date
BG103722A true BG103722A (en) 2000-06-30

Family

ID=10807635

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103722A BG103722A (en) 1997-02-14 1999-09-09 Penylxanthine esters and amides

Country Status (38)

Country Link
US (3) US6355646B1 (sh)
EP (1) EP0970081B1 (sh)
JP (1) JP2001511792A (sh)
KR (1) KR100522639B1 (sh)
CN (1) CN1140527C (sh)
AP (1) AP1000A (sh)
AR (1) AR011441A1 (sh)
AT (1) ATE304542T1 (sh)
AU (1) AU754456B2 (sh)
BG (1) BG103722A (sh)
BR (1) BR9807682B1 (sh)
CA (1) CA2280730C (sh)
CO (1) CO4940444A1 (sh)
CZ (1) CZ298764B6 (sh)
DE (1) DE69831559T2 (sh)
DK (1) DK0970081T3 (sh)
EA (1) EA199900648A1 (sh)
EE (1) EE9900348A (sh)
ES (1) ES2249822T3 (sh)
GB (1) GB9703044D0 (sh)
HK (1) HK1022907A1 (sh)
HR (1) HRP980077A2 (sh)
HU (1) HU225962B1 (sh)
ID (1) ID22770A (sh)
IL (1) IL131179A (sh)
IS (1) IS5144A (sh)
MY (1) MY118545A (sh)
NO (1) NO325685B1 (sh)
NZ (1) NZ336923A (sh)
PE (1) PE58899A1 (sh)
PL (1) PL188018B1 (sh)
SK (1) SK110399A3 (sh)
TR (1) TR199901942T2 (sh)
TW (1) TW520371B (sh)
UA (1) UA57767C2 (sh)
WO (1) WO1998035966A1 (sh)
YU (1) YU38399A (sh)
ZA (1) ZA981175B (sh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
FR2804958B1 (fr) * 2000-02-15 2005-07-08 Hoechst Marion Roussel Inc Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant
WO2002067942A2 (en) * 2001-02-28 2002-09-06 Smithkline Beecham Corporation Methods of treating irritable bowel syndrome and functional dyspepsia
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20040072848A1 (en) * 2002-02-26 2004-04-15 Huber Brian E Methods of treating irritable bowel syndrome and functional dyspepsia
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
AU2012227249B2 (en) * 2003-12-16 2014-10-02 Nektar Therapeutics Chemically modified small molecules
CN1925875A (zh) * 2003-12-16 2007-03-07 尼克塔治疗亚拉巴马公司 化学改性的小分子
WO2005102976A1 (en) * 2004-04-21 2005-11-03 Smithkline Beecham Corporation Process for preparing nonaethylene glycol monomethyl ether
MX2007002437A (es) * 2004-09-01 2007-08-14 Cv Therapeutics Inc Metodo para el sanado de heridas utilizando antagonistas del receptor de adenosina a2b.
US20070059740A1 (en) * 2005-08-26 2007-03-15 Linden Joel M Method of targeting a2b adenosine receptor antagonist therapy
US8193200B2 (en) * 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
US4968672A (en) 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5015647A (en) 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
GB8826595D0 (en) 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
TW252044B (sh) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
GB9415529D0 (en) 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
DK0812844T3 (da) 1996-06-07 2003-02-17 Hoechst Ag Anvendelse af theophyllinderivater til behandling og profylakse af choktilstande, nye xanthinforbindelser og fremgangsmåder til deres fremstilling
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
AU2640999A (en) 1998-02-26 1999-09-15 Zenyaku Kogyo Kabushiki Kaisha 1-azaindolizine derivatives
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
EP1246621A4 (en) 1999-12-23 2004-11-24 Nitromed Inc NITROSED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS FOR THEIR USE
US6751206B1 (en) * 2000-06-29 2004-06-15 Qualcomm Incorporated Method and apparatus for beam switching in a wireless communication system

Also Published As

Publication number Publication date
DE69831559D1 (de) 2005-10-20
CZ298764B6 (cs) 2008-01-23
EP0970081A1 (en) 2000-01-12
HU225962B1 (en) 2008-01-28
JP2001511792A (ja) 2001-08-14
US6437124B1 (en) 2002-08-20
AP1000A (en) 2001-08-11
KR100522639B1 (ko) 2005-10-19
IL131179A (en) 2004-05-12
PL188018B1 (pl) 2004-11-30
PL335135A1 (en) 2000-04-10
EA199900648A1 (ru) 2000-04-24
IS5144A (is) 1999-07-30
CN1252071A (zh) 2000-05-03
CA2280730A1 (en) 1998-08-20
BR9807682B1 (pt) 2009-01-13
BR9807682A (pt) 2000-02-15
SK110399A3 (en) 2000-06-12
UA57767C2 (uk) 2003-07-15
HRP980077A2 (en) 1998-12-31
ATE304542T1 (de) 2005-09-15
US20030181471A1 (en) 2003-09-25
US7002012B2 (en) 2006-02-21
AU6622198A (en) 1998-09-08
TR199901942T2 (xx) 1999-12-21
US6355646B1 (en) 2002-03-12
KR20000071010A (ko) 2000-11-25
TW520371B (en) 2003-02-11
IL131179A0 (en) 2001-01-28
HK1022907A1 (en) 2000-08-25
CZ288799A3 (cs) 2000-04-12
HUP0000894A2 (hu) 2001-05-28
CA2280730C (en) 2006-10-10
MY118545A (en) 2004-12-31
PE58899A1 (es) 1999-06-17
NO325685B1 (no) 2008-07-07
ES2249822T3 (es) 2006-04-01
AR011441A1 (es) 2000-08-16
DE69831559T2 (de) 2006-06-14
NO993915L (no) 1999-10-13
CN1140527C (zh) 2004-03-03
HUP0000894A3 (en) 2002-04-29
CO4940444A1 (es) 2000-07-24
DK0970081T3 (da) 2006-02-06
EP0970081B1 (en) 2005-09-14
GB9703044D0 (en) 1997-04-02
WO1998035966A1 (en) 1998-08-20
ZA981175B (en) 1999-08-12
YU38399A (sh) 2002-06-19
EE9900348A (et) 2000-02-15
AU754456B2 (en) 2002-11-14
NZ336923A (en) 2001-02-23
AP9901622A0 (en) 1999-09-30
ID22770A (id) 1999-12-09
NO993915D0 (no) 1999-08-13

Similar Documents

Publication Publication Date Title
BG103722A (en) Penylxanthine esters and amides
AU2284099A (en) Poly-aminoacid derivatives and their use in compositions for treating keratinousfibres
MX9805181A (es) Derivados de lactona a partir de derivados de 17.beta- carboxi, carbotio y amida androstano.
DK0695758T3 (da) Pentapeptidamider og -estere til inhibering af human cancer
PL339701A1 (en) Acylosulphamoybenzamides, crop protection products containing them and method of obtaining such crop protection products
ES2173185T3 (es) Empleo de derivados de tetrahidropteridina como inhibidores de la no-sintasa.
ATE248175T1 (de) Epothilonderivate und ihre verwendung als antitumormittel
NO179142C (no) 3-benzyliden-1-karbamoyl-2-pyrrolidon-analoger
PT839154E (pt) Peptidos e composicoes biologicamente activos sua utilizacao
IS4384A (is) Ensím latar
TR199800602A2 (xx) Dithiolan t�revleri, haz�rlanmalar� ve terap�tik etkileri.
MX235505B (sh)
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
TR199901765T2 (xx) S�lfomid-metalloproteaz inhibit�rleri
DK1144365T3 (da) Inhibitorer af alfa4beta1-medieret celleadhæsion
AP2000001761A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
TR199701013T1 (xx) Nitrik oksit synthas'�n�n inhibit�rleri olarak mercapto ve seleno t�revleri.
DE69418744D1 (de) Verwendung von Pregnanderivaten zur Behandlung von Tumoren
DK0532530T3 (da) Derivater af 6-amino-octahydroindolizintriol
MY128261A (en) New substituted azetidinones as anti-inflammatory and antidegenerative agents
BG103271A (en) Derivatives of n-(benzothiazol-2-yl) piperidine-1-ethaneamines, method for their preparation and application as therapeutical means
FI944018A (fi) Nikkeli-molybdeenilejeerinkejä
BG101942A (en) Analogues of arginine having inhibiting activity on no-synthetase
BG103395A (en) Derivatives of benzenesulphonamide and medicaments containing them
IL117497A0 (en) 17-Difluoromethylene estratriene derivatives and pharmaceutical compositions containing the same